In an age of greenwashing, where ESG (environmental, social, governance) increasingly feels like a corporate buzzword, how do you find the companies that are not only talking the talk, but
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
